Incyte to Showcase Oncology Data at ESMO 2026 with Focus on Hard-to-Treat Cancers
Event summary
- Incyte will present data from six oncology programs at ESMO Congress 2026, including four rapid oral presentations.
- Key focus areas include KRAS G12D inhibitor for pancreatic and colorectal cancer, TGFβR2×PD-1 bispecific antibody for microsatellite stable colorectal cancer, and CDK2 inhibitor for ovarian cancer.
- Presentations scheduled between October 23–27, 2026, in Madrid.
- Data highlights include combination therapies with existing treatments like cetuximab and bevacizumab.
The big picture
Incyte's focus on difficult-to-treat cancers aligns with the broader industry trend of targeting high-unmet medical needs in oncology. The company's emphasis on combination therapies reflects a strategic shift towards leveraging existing treatments to enhance efficacy, potentially reducing development timelines and costs. Success in these areas could solidify Incyte's position as an innovator in precision oncology.
What we're watching
- Clinical Efficacy
- How the efficacy data for INCB161734 in pancreatic and colorectal cancer will position Incyte against competitors.
- Combination Therapy Potential
- Whether the combination therapies with existing treatments like cetuximab and bevacizumab can enhance outcomes in difficult-to-treat cancers.
- Regulatory Pathways
- The pace at which Incyte can advance these investigational therapies through regulatory approvals based on ESMO data.
Related topics